Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™, a patented resveratrol-based platform, is pleased to announce that ...

Minerva Neurosciences (NERV) stock is down ~34% since Aug 2022 amid sharp volatility and no clear catalysts. Click here to ...

FUTRUE Neurosciences has achieved its first milestone on its mission to become the global leader in modern brain-computer ...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim ...

The average one-year price target for Minerva Neurosciences (NasdaqCM:NERV) has been revised to $7.40 / share. This is an ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

Drexel University College of Medicine is pleased to announce the launch of the Drexel Neurosciences Institute, an innovative collaboration of Drexel's College of Medicine and Global Neurosciences ...

View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.

The average one-year price target for ProMIS Neurosciences (NasdaqCM:PMN) has been revised to $35.06 / share. This is a decrease of 57.76% from the prior estimate of $83.00 dated February 21, 2026.

Enter The Neurosciences Institute’s curved central courtyard and you may feel you’re being choreographed across a dynamic, multilevel stage with slanted walks and a surprise waterfall. Or you may be ...

Patients will be on the move Wednesday at Ascension Alexian Brothers hospital in Elk Grove Village, where a new 36-bed neurosciences unit opens. The 24,000-square-foot space encompasses the fifth ...